Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of [14C] XZP-3287 in Healthy Males
NCT05478109Phase 1Unknown
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Aug 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of birociclib in breast cancer, sponsored by Xuanzhu Biopharmaceutical. Primary endpoints: Peak Plasma Concentration (Cmax) of [14C]XZP-3287 up to 15 days, Area Under the Curve to Last Quantifiable Concentration (AUClast) of [14C]XZP-3287 up to 15 days and 3 more. Status: unknown.
02
Drugs
birociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05478109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478109.